Judith K. Evans

4.0k total citations · 1 hit paper
34 papers, 3.1k citations indexed

About

Judith K. Evans is a scholar working on Surgery, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Judith K. Evans has authored 34 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 10 papers in Physiology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Judith K. Evans's work include Nausea and vomiting management (24 papers), Anesthesia and Pain Management (20 papers) and Pathogenesis and Treatment of Hiccups (6 papers). Judith K. Evans is often cited by papers focused on Nausea and vomiting management (24 papers), Anesthesia and Pain Management (20 papers) and Pathogenesis and Treatment of Hiccups (6 papers). Judith K. Evans collaborates with scholars based in United States, Netherlands and Canada. Judith K. Evans's co-authors include Kevin Horgan, Alexandra D. Carides, Ronald de Wit, Paul J. Hesketh, M. Elmer, Richard J. Gralla, A. Carides, Steven M. Grunberg, Sant P. Chawla and Francesca Lawson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Gastroenterology.

In The Last Decade

Judith K. Evans

33 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

2003 593 citations Paul J. Hesketh, Steven M. Grunberg et al. profile →

Peers

Countries citing papers authored by Judith K. Evans

Since Specialization

Citations

This map shows the geographic impact of Judith K. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith K. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith K. Evans more than expected).

Fields of papers citing papers by Judith K. Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith K. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith K. Evans. The network helps show where Judith K. Evans may publish in the future.

Co-authorship network of co-authors of Judith K. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Judith K. Evans. A scholar is included among the top collaborators of Judith K. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith K. Evans. Judith K. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictors of Adherence to Triptans: Factors of Sustained vs Lapsed Users 2009 ·Headache The Journal of Head and Face Pain ·Roger Cady, Morris Maizels, Dennis Reeves, Daniel M. Levinson, Judith K. Evans	31
2	Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects 2009 ·Anesthesia & Analgesia ·Thomas Marbury, Bo Jin, Deborah Panebianco, M. Gail Murphy, Hong Sun, Judith K. Evans, Tae Hyung Han, M.L. Constanzer, (unknown), (unknown)	13
3	Migraine strikes study: factors in patients’ decision to treat early 2009 ·The Journal of Headache and Pain ·Wendy L. Golden, Judith K. Evans, Henry Hu	6
4	Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerability 2008 ·Pediatric Blood & Cancer ·Lia Gore, Sant P. Chawla, Antônio Sérgio Petrilli, Molly Hemenway, (unknown), (unknown), Alexandra D. Carides, Arlene Taylor, (unknown), J L Valentine, Judith K. Evans, Bettina Oxenius, (unknown)	66
5	A Randomized, Double-Blind Comparison of the NK1 Antagonist, Aprepitant, Versus Ondansetron for the Prevention of Postoperative Nausea and Vomiting 2007 ·Anesthesia & Analgesia ·Tong J. Gan, Christian C. Apfel, Anthony L. Kovac, Beverly K. Philip, Neil Singla, Harold S. Minkowitz, Ashraf S. Habib, (unknown), Alexandra D. Carides, Hong Zhang, Kevin Horgan, Judith K. Evans, (unknown)	128
6	Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery † 2007 ·British Journal of Anaesthesia ·Pierre Diemunsch, Tong J. Gan, B. K. Philip, Manoel Joâo Batista Castello Girão, Leopold Eberhart, Michael G. Irwin, (unknown), Jacques E. Chelly, A. Carides, Theodore F. Reiss, Judith K. Evans, Francesca Lawson	119
7	Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects 2007 ·The Journal of Clinical Pharmacology ·Kenneth C. Lasseter, (unknown), Bo Jin, (unknown), M.L. Constanzer, (unknown), Tae Hyung Han, Anup Majumdar, Judith K. Evans, M. Gail Murphy	88
8	Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant 2007 ·Current Medical Research and Opinion ·Pierre Diemunsch, Christian C. Apfel, Tong J. Gan, Keith Candiotti, Beverly K. Philip, Jacques E. Chelly, Alexandra D. Carides, Judith K. Evans, Tony W. Ho, Theodore F. Reiss	39
9	The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials 2005 ·European Journal of Cancer ·David Warr, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, Fausto Roila, Ronald de Wit, Alexandra D. Carides, Arlene Taylor, Judith K. Evans, Kevin Horgan	100
10	Antiemetic efficacy of the neurokinin‐1 antagonist, aprepitant, plus a 5HT₃ antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high‐dose cisplatin 2005 ·Cancer ·Richard J. Gralla, Ronald de Wit, Jørn Herrstedt, Alexandra D. Carides, Juliana Ianus, (unknown), Judith K. Evans, Kevin Horgan	81
11	Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity 2004 ·The Journal of Clinical Pharmacology ·(unknown), Yih Lee, Anup Majumdar, Kevin J. Petty, Cynthia Gargano, Thomas E. Bradstreet, Judith K. Evans, Robert A. Blum	88
12	Aprepitant: An oral NK1 antagonist for the prevention of nausea andvomiting induced by highly emetogenic chemotherapy 2004 ·Drugs of today ·Kelly Pendergrass, Richard Hargreaves, Kevin J. Petty, Alexandra D. Carides, Judith K. Evans, Kevin Horgan	24
13	The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events 2003 ·The American Journal of Gastroenterology ·Richard H. Hunt, S. E. Harper, Douglas J. Watson, Chang Yu, Hui Quan, Michael Lee, Judith K. Evans, Bettina Oxenius	122
14	Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting 2003 ·Cancer ·(unknown), (unknown), Alexandra D. Carides, (unknown), (unknown), (unknown), Judith K. Evans, Kevin Horgan, Francesca Lawson, (unknown)	459
15	Establishing the dose of the oral NK₁ antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting 2003 ·Cancer ·Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, (unknown), M. Elmer, (unknown), Arlene Taylor, Alexandra D. Carides, Judith K. Evans, Kevin Horgan	177
16	Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib 2003 ·Alimentary Pharmacology & Therapeutics ·Richard H. Hunt, S. E. Harper, (unknown), Chang Yu, Hui Quan, Judith K. Evans, (unknown), B.M. Bowen, (unknown)	87
17	Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists 2003 ·European Journal of Cancer ·Paul J. Hesketh, Simon Van Belle, Matti Aapro, F.D. Tattersall, R.J. Naylor, Richard Hargreaves, A. Carides, Judith K. Evans, Kevin Horgan	208
18	Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 ·Kevin Horgan, Kevin J. Petty, Anup Majumdar, Scott A. Reines, Judith K. Evans	1
19	Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869 2002 ·Cancer ·Simon Van Belle, M. Lichinitser, Rudolph M. Navari, August Garin, Marc Decramer, Alain Rivière, Myo Thant, (unknown), Binh Bui, (unknown), Marina De Smet, N. Michiels, (unknown), Alexandra D. Carides, Judith K. Evans, Barry J. Gertz	115
20	Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double‐Blind, Placebo‐Controlled Study 2002 ·Headache The Journal of Head and Face Pain ·Paul Winner, Donald W. Lewis, W. Hester Visser, Kaihong Jiang, (unknown), Judith K. Evans, (unknown)	117

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact